What is Leerink Partnrs' Estimate for CLDX FY2028 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs lowered their FY2028 EPS estimates for shares of Celldex Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will earn $0.95 per share for the year, down from their previous estimate of $0.99. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics' FY2029 earnings at $6.62 EPS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million.

CLDX has been the topic of a number of other reports. The Goldman Sachs Group dropped their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research note on Monday. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price for the company. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $55.38.

Remove Ads

Celldex Therapeutics Trading Up 3.0 %

Shares of NASDAQ CLDX traded up $0.64 during mid-day trading on Monday, reaching $21.74. The company had a trading volume of 229,183 shares, compared to its average volume of 894,870. Celldex Therapeutics has a 52 week low of $18.61 and a 52 week high of $49.65. The business's 50-day moving average is $23.56 and its 200-day moving average is $28.64. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -8.42 and a beta of 1.76.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. KBC Group NV lifted its position in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 495 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $81,000. AlphaQuest LLC grew its position in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.